Fig. 4

Enhanced survival of CTX-R gene-modified primary murine hematopoietic cells during myeloid differentiation. Non-sorted genetically modified lin⁻ cells were subjected to myeloid differentiation in suspension culture in the presence of cytotoxic drugs. a LV.SFFV.MDR1 as well as LV.SFFV.GFP gene-modified cells were treated with daunorubicin monotherapy (n = 4–7), and (b) LV.SFFV.CDD as well as LV.SFFV.GFP transduced cells were treated with Ara-C monotherapy (n = 7). LV.SFFV.CDD.2A.MDR1 as well as LV.SFFV.GFP were treated with (c) daunorubicin (n = 6), (d) Ara-C monotherapy (n = 7–12) or (e) daunorubicin/Ara-C combination therapy (n = 5–6). Data are presented as mean ± SD; *p ≤ 0.05/** p ≤ 0.01 denote significant differences compared to LV.SFFV.GFP control (calculated by ANOVA)